BFM
SYRS

Boothbay Fund Management’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Boothbay Fund Management’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,030
Closed -$77K – 2174
2021
Q1 		$77K Hold
1,030
– – ﹤0.01% 1486
2020
Q4 		$112K Buy
+1,030
New +$94K ﹤0.01% 1175

Other funds holding SYRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Boothbay Fund Management's SYRS Position: Q2 2021 in Review

Boothbay Fund Management sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q2 2021, closing a stake of 1,030 shares — an estimated $77K sold.

Boothbay Fund Management first reported a position in SYRS in Q4 2020 and held it in 2 quarters. The position peaked at $112K in Q4 2020. 100 funds tracked by Wall St. Rank hold SYRS as of Q2 2021.

  • Boothbay Fund Management reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Boothbay Fund Management sold 1,030 Syros Pharmaceuticals, Inc. Common Stock shares in Q2 2021, an estimated $77K.
  • Boothbay Fund Management first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2020 and held it in 2 quarters.
  • Boothbay Fund Management's Syros Pharmaceuticals, Inc. Common Stock position peaked at $112K in Q4 2020.
  • 100 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q2 2021.

Based on Boothbay Fund Management's 13F filing for Q2 2021, filed 16 Aug 2021.